



Market Announcement

17 April 2019

Admedus Ltd (ASX: AHZ) – Suspension from Official Quotation

Description

The securities of Admedus Ltd ('AHZ') will be suspended from quotation immediately under Listing Rule 17.2, at the request of AHZ, pending the release of an announcement regarding the Immunotherapies Transaction.

Issued by

Isabelle Andrews

Adviser, Listings Compliance (Perth)

Ms Anjuli Sinniah
Senior Adviser, Listings Compliance
ASX Limited
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

17 April 2019

By Email: ListingsCompliancePerth@asx.com.au
tradinghaltspert@asx.com.au

Dear Ms Sinniah

ADMEDUS LTD (ASX:AHZ) - REQUEST FOR VOLUNTARY SUSPENSION

Admedus Limited (the **Company**) refers to the trading halt granted on 15 April 2019.

Pursuant to Listing Rule 17.2, the Company requests a voluntary suspension of the quotation of its securities effective from the commencement of trading on 17 April 2019.

The Company advises that:

- (a) the voluntary suspension is necessary for the Company to conclude discussions with Constellation Therapeutics Limited (**Constellation**) in relation to the share sale agreement entered into by its wholly owned subsidiary Admedus Investments Pty Ltd (**AIPL**) and the other shareholders of Admedus Vaccines Pty Ltd (**Admedus Vaccines**) for the sale of all of the shares of Admedus Vaccines (the **Immunotherapies Transaction**). Constellation has indicated that as all the conditions to the Immunotherapies Transaction have not yet been satisfied, it may not wish to conclude the Immunotherapies Transaction on the current terms as previously announced to ASX, and instead pursue an alternative transaction, the details of which are currently uncertain;
- (b) the Company expects the suspension to last until the earlier of the commencement of normal trading on 26 April 2019, or the release of an announcement by the Company;
- (c) the Company is not aware of any reason why its securities should not be suspended from quotation; and

Admedus Limited


Registered Office:

Toowong Tower, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@admedus.com W: admedus.com



(d) the Company is not aware of any further information necessary to inform the market about the voluntary suspension.

Yours sincerely

A handwritten signature in black ink, appearing to be "S. Denaro", written on a light grey rectangular background.

Steve Denaro

Company Secretary